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Abstract
Background: Despite advances in medical knowledge, technology and antimicrobial therapy, infective endocarditis
(IE) is still associated with devastating outcomes. No reviews have yet assessed the outcomes of IE patients undergoing
short- and long-term outcome evaluation, such as all-cause mortality and IE-related complications. We conducted a
systematic review and meta-analysis to examine the short- and long-term mortality, as well as IE-related complications
in patients with definite IE.
Methods: A computerized systematic literature search was carried out in PubMed, Scopus and Google Scholar from
2000 to August, 2016. Included studies were published studies in English that assessed short-and long-term mortality
for adult IE patients. Pooled estimations with 95% confidence interval (CI) were calculated with DerSimonian-Laird (DL)
random-effects model. Sensitivity and subgroup analyses were also performed. Publication bias was evaluated using
inspection of funnel plots and statistical tests.
Results: Twenty five observational studies (retrospective, 14; prospective, 11) including 22,382 patients were identified.
The overall pooled mortality estimates for IE patients who underwent short- and long-term follow-up were
20% (95% CI: 18.0–23.0, P < 0.01) and 37% (95% CI: 27.0–48.0, P < 0.01), respectively. The pooled prevalence of
cardiac complications in patients with IE was found to be 39% (95%CI: 32.0–46.0) while septic embolism and
renal complications accounted for 25% (95% CI: 20.0–31) and 19% (95% CI: 14.0–25.0) (all P < 0.01),
respectively.
Conclusion: Irrespective of the follow-up period, a significantly higher mortality rate was reported in IE patients, and
the burden of IE-related complications were immense. Further research is needed to assess the determinants of overall
mortality in IE patients, as well as well-designed observational studies to conform our results.
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Background
Infective endocarditis (IE) is an infection of the
endocardial lining of the heart with pre-existing le-
sions or on intra-cardiac foreign materials [1]. Bac-
terial species such as staphylococcus and
streptococcus accounts for 80% of cases; however, it
may occasionally be due to fungal pathogens as well
[1, 2]. The Global Burden of Diseases Study—GBD
2010 reported a crude IE incidence ranged between
1.5 to 11.6 cases per 100,000 people and the mean
proportion of patients that underwent valve surgery
was 32.4 ± 18.8%, and the mean fatality risk was 21.1
± 10.4% [3]. The presence of rheumatic heart disease,
congenital heart disease, prosthetic valves and
previous episodes of IE are some of the traditional
risk factors; however, predisposing factors such as
intra-cardiac devices, intravenous drug use, human
immune virus (HIV) infection, diabetes, hemodialysis,
degenerative valvular heart disease and dental
* Correspondence: abegaztadesse981@gmail.com
1Department of Clinical pharmacy, School of Phamacy, College of Medicine
and Health Sciences, University of Gondar, Gondar, Ethiopia
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Abegaz et al. BMC Cardiovascular Disorders  (2017) 17:291 
DOI 10.1186/s12872-017-0729-5
infection are some of the risk factors that predomi-
nates over the traditional risk factors [2].
Clinical suspicion of IE is very often delayed be-
cause early clinical symptoms are not properly evalu-
ated and present as a subacute disease with
symptoms like fever and malaise that does not cor-
respond to a serious disease. Blood culture-positive
endocarditis (BCPE) and blood culture-negative
endocarditis (BCNE) remain the cornerstone of diag-
nosis and provide significant array for identification
and susceptibility testing. IE can mimic many dis-
eases and prompt diagnosis remains a challenge with
high in-hospital morbidity and mortality, and com-
promised short-term outcomes after hospital
discharge [4]. Delay in antibiotic therapy and
inappropriate antibiotics in suspected IE cases has
negative effects on clinical outcomes in acute stage
[5]. Successful microbial eradication by antimicrobial
drugs or by surgical removal of infected materials
and draining abscesses are essential for positive
outcomes.
Despite advances in medical knowledge, technology
and antimicrobial therapy, IE is still associated with
devastating outcomes and becoming a pressing prob-
lem, with at least one in four died of IE [3]. The in-
hospital mortality (22%) and 5-year mortality (45%)
was significantly higher in IE cases, with an annual
deaths of 48,300 patients globally in 2010 [6]. In fact,
several discrepancies have been noticed in the litera-
ture concerning the impact of guidelines, recommen-
dations, risk estimations and research findings
estimating the outcomes in IE [7–11]. Several reviews
were focused examining the effect of different anti-
biotic regimens [12], optimal timing of surgery [13],
epidemiology [14] and effect of surgical intervention
[15]. However, no reviews have yet assessed the
outcomes of IE patients undergoing short-term and
long-term treatment, heart valve involvement and
outcomes in intravenous drug users. We, therefore,
conducted a systematic review and meta-analysis in-
cluding a wide variety of studies examining the
short-term and long-term outcomes in IE patients.
The main outcome measures were clinical outcomes
and overall mortality.
Methods
Data sources and search strategy
A computerized systematic literature search was car-
ried out using the scientific databases: PubMed,
Scopus and Google Scholar. We exhaustively searched
the databases for studies published between 2000 to
August, 2016 using the following key words: ‘infective
endocarditis’ in conjunction with search terms such
as ‘long- or short-term outcome’, ‘prognosis’, ‘in-hos-
pital’, ‘mortality’, ‘native valve’, ‘prosthetic valve’, and
‘drug users’.
Study selection and eligibility
Study selection
All records that were identified from searches of the
electronic databases were loaded into the ENDNOTE
software version X5 (Thomson Reuters, USA) and
duplicates were removed. Two author (TMA and
EAG) screened the titles and abstract of each refer-
ence identified by applying the inclusion criteria.
Two authors (TMA and TBA) independently
collected the full-text and reviewed them. Final inclu-
sion of the studies was determined by agreement of
both reviewers and involvement of the third author
(EAG) in case of discrepancy. All the authors
involved in the discussion and agreed on the final
inclusion.
Inclusion and exclusion criteria
Literature reviews and studies with only surgical
intervention were excluded. But, if both medical and
surgical interventions were undertaken for a patient,
the study was included. Studies that did not deter-
mine the short- or long-term outcome were excluded.
For outcome evaluation, patients with definite IE and
patients who fulfilled the modified Duke criteria for
diagnosis of IE, were considered. We also included
studies that assessed IE in Intravenous (IV) drug
users and those with prosthetic device. Age was lim-
ited to adults and our search term did not include
children or pediatrics. Only studies published in
English were considered eligible. In addition, studies
with small samples size (less than 50) were excluded
to maintain the quality of our findings.
Data extraction and quality assessment
Data on socio-demographic characteristics including
age, sex, study design, study setting, and mean
follow-up period were retrieved. Clinical profiles of
patients such as the type of valve affected, bacterial
profile and primary outcomes including short-and
long-term mortality were extracted. Mortality is in-
cluded as all-cause mortality. Mortality within 30 days
of admission and in-hospital mortality was classified
as ‘short-term’ mortality but if both in-hospital mor-
tality and the 30 day mortality was given, the latter
was chosen. Whereas, long-term mortality denotes
mortality after patients have been discharged from
the hospital and died after 30 days of follow-up. For
ease of analysis, studies that reported the long-term
outcome at various time intervals, we employed the
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longer duration of time in the analysis. Also, second-
ary outcomes were collated and defined in this study
as complications due to IE such as cardiac damage,
renal failure and embolic complications.
The quality of the studies was evaluated using
STROBE (Strengthening the Reporting of Observational
Studies in Epidemiology) scale [16]. Accordingly, we
arbitrarily classified included studies into high quality
(≥75% of the STROBE checklist) and low quality (<75%
of the STROBE checklist).
Statistical analysis
The meta-analysis was carried out with OpenMetaA-
nalyst (http://www.cebm.brown.edu/openmeta) and
publication bias was assessed using Comprehensive
Meta-analysis version-3 (Biostat, Englewood, New
Jersey, USA). The random effects model was used
for combining results of included studies in the
meta-analysis. The heterogeneity in pooled estima-
tion was determined by the DerSimonian-Laird (DL)
approach and was assessed using I2. Sensitivity and
subgroup analyses were conducted to determine the
robustness of the results and sources of variation in
pooled estimation, respectively. Initially, we planned
to stratify primary and secondary outcomes on the
basis of various sources of variation such as sex, age,
and types of IE. However, included studies did not
provide these data in extractable form and/or be-
cause there were inconsistencies in reporting the
subgroups, we did not able to conduct subgroup
analysis for our primary and secondary outcomes.
On post hoc analysis, rather we conducted subgroup
analysis based on the incidence and prevalence of
IEs, stratified according to sex (male vs. female) and
types of IE (native, prosthetic and drug users).
Moreover, publication bias for the primary outcome
was assessed by Egger and Begg’s tests and inspec-
tion of funnel plots.
Results
A total of 4466 unique articles were identified from
three databases: PubMed (3334), Scopus (378) and
Google Scholar (754), of which fifty-one deemed eli-
gible for the full-text review and twenty-five articles
were finally included in the systematic review and
meta-analysis (Fig. 1).
Characteristics of included studies
Overall, 15 included studies were from Europe [17–31],
six from Asia [32–37], one from Africa [38], and the re-
mainder studies were intercontinental encompassing
many countries [39–41]. We identified 14 retrospective
and 11 prospective studies. The sample sizes in the in-
cluded studies ranged from 66 (minimum) [34] to 8494
(maximum) [33]. A total number of 22,382 patients were
included in the review. The mean age of the study
subjects in the studies ranged from nearly 23
to 80 years of age [17, 23], with 42% to 80% males
[21, 32]. All but one study [27] reported short-term
outcome. Whereas, 14 studies estimated long-term
outcome [17–20, 22–30, 39]. Three studies [22, 27, 29]
estimated ten year outcome and six studies [17, 23–25, 28,
29] assessed five year outcome, and the remainder studies
[18, 22, 25–27, 39] evaluated this outcome at one year.
Secondary outcomes (complications of IE) were also
evaluated in 17/25 of the included studies. The
methodological qualities of included studies were variable
and there was none that met the complete STROBE
criteria (Table 1).
Fig. 1 Flow chart indicating the selection process of studies
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Clinical characteristics and risk factors
A total of 1974 (8.8%) patients were having IE due
to mitral valve infection while 2162 (9.7%) were due
to aortic valve involvement, and combination of
valves were reported in 18,246 (81.5%) patients.
While 2278 (10.2%) patients had acquired left sided
Table 1 Overview of studies included in the systematic review and meta-analysis




















Prospective Sweden 7603 65.7 41:59 √ √ – – – 86
Martinez-Sellés
et al. 2008 [18]
Prospective Spain 222 63.5 ± 15.5 36:64 √ √ – – – 73
Fernandez-Hidalgo
et al. 2012 [19]
Prospective Spain 438 – 35:65 √ √ – – – 91
Samol et al. 2015
[20]





106 57 ± 14.8 20:80 √ – √ √ – 82
Thuny et al.
2008 [22]
Prospective France 95 53 ± 16 27:73 √ √ – √ √ 82
Remadi et al.
2009 [23]
Prospective France 348 79.8 ± 4 28:72 √ √ √ √ √ 91
Krecki et al.
2007 [24]
Retrospective Poland 69 52 ± 12 41:59 √ √ √ √ – 77
Moreno et al.
2002 [25]
Prospective Spain 151 66 ± 11
versus 50 ±
19 years
34:66 √ √ √ √ √ 78
Tran et al.
2006 [26]
Retrospective Denmark 132 54 (range:
19–83)
37:63 √ √ – – – 64
Mirabel et al.
2014 [27]
Prospective France 198 61.1 (range:
15.5–71)
30:70 – √ √ √ – 95
Ferreira et al.
2013 [28]
Prospective Portugal 147 63 ± 11 29:71 √ √ – √ √ 82
Leroy et al.
2015 [29]
Retrospective France 248 62.4 ± 13.3 36:64 √ √ √ √ √ 77
Netzer et al.
2002 [30]





208 52 ± 1.2 34:66 √ – – – – 68
Khaled et al.
2010 [32]





Taiwan 8494 56.2 ± 19.2 36:64 √ – √ √ √ 82
Tariq et al.
2004 [34]
Retrospective Pakistan 66 28.6 ± 12.3 33:67 √ – – – – 64
Tariq et al. [35] Retrospective Pakistan 159 34.6 ± 20.7 35:65 √ – – – – 76
Garg et al.
2005 [36]
Retrospective India 192 27.6 ± 12.7 27:73 √ – √ √ √ 73
Math et al.
2010 [37]
Prospective India 104 23.3 ± 9.56 29:71 √ – √ √ √ 73
Letaief et al.
2007 [38]
Retrospective Tunisia 435 32.4 ± 16.8 44:56 √ – – √ √ 77
Athan et al.
2012 [39]
Prospective Multicounty 177 – 26:74 √ √ – – – 79
Lauridsen et al.
2015 [40]
Prospective Multicounty 727 – 31:69 √ – – √ √ 95
Lalani et al.
2010 [41]
Prospective Multicounty 1552 57 31:69 √ – – √ √ 95
√- denotes inclusion in the respective studies; (−) refers ‘not stated’
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IE, the remaining constituted both left and right
sided IE, 20,104 (89.8%). Besides medical interven-
tion, only 3496 (15.6%) patients underwent surgical
intervention.
Data from 10,987 patients were available to deter-
mine the types of IE. Of these, 8496 (77.3%) had na-
tive valve IE and prosthetic valve IE was identified in
1414 (12.9%) patients. Whereas, IE due to intravenous
drug use was reported in 1077 (9.8%) subjects. Other
patients, 11,395 (of the 22,382) had either mixed type
or unclassified IE.
A total of 5011 (22.4%) patients were identified to
have risk factors including congenital heart disease
(CHD) which was reported as a predisposing factor in
220 patients, whereas rheumatic heart disease (RHD)
was reported in 513 cases. About 63 patients experi-
enced previous episodes of IE.
Common pathogens involved in IE
Most of the studies did not report the number of
species involved in causing IEs. Among the studies
that reported culture results, it was found that 63%
(1320/2012) cases were positive and negative in 21%
(1049/12,508) subjects. Culture was not performed
or adequately documented in the rest of individuals.
Among the reported pathogens, the dominant strain
was Staphylococcus aureus (2894/13,768; 27%)




In total, the population for the assessment of mor-
tality consisted of 22,382 subjects for both long- and
short-term outcomes. Short-term outcome was deter-
mined by analyzing the data of 22,184 patients ob-
tained from 24 studies, whereas long-term mortality
was analyzed using the 10,256 patients included
from 14 studies. Short-term mortality occurred in
3369 patients while long-term follow-up resulted in
death of 2174 patients. The overall pooled mortality
estimates for IE patients who underwent short- and
long-term follow-up were 20% (95% CI: 18.0–23.0, P
< 0.01; heterogeneity I2 = 94.0%) and 37% (95% CI:
27.0–48.0, P < 0.01; heterogeneity I2 = 98.9%), respect-
ively (Figs. 2 and 3).
Secondary outcomes
Complication of IE including renal, cardiac and embolic
(septic) were evaluated in 13,637 patients, of which at
least one complication was reported in 10,483 (76.9%)
patients. The pooled prevalence of cardiac complications
in patients with IE was found to be 39% (95%CI:
32.0–46.0, P < 0.01; heterogeneity I2 = 98.2%) while sep-
tic embolism and renal complications of IE accounted
for 25% (95% CI: 20.0–31, P < 0.01; I2 = 97.1%) and 19%
(95% CI: 14.0–25.0, P < 0.01; heterogeneity I2 = 94.9%),
respectively (Figs. 4, 5 and 6).
Sensitivity and subgroup analysis
The sensitivity analysis showed that omission of any-
one of the included studies did not affect the pooled
results for both primary and secondary outcomes (all
P < 0.05). We performed subgroup analysis in those
studies which clearly reported the types of IEs.
Accordingly, the most frequently reported type of IE
was native valve, occurred in 74% (95% CI: 64–84) of
patients followed by prosthetic valve IE, 19% (95% CI:
14–23). In terms of sex, subgroup analysis showed
that a significantly higher IE rate was reported in
males than in females (OR: 4.1; 95% CI: 3.38–4.97)
(Appendix 1).
Publication bias
Funnel plots supplemented by statistical tests
confirmed there existed some evidence of publication
bias in the mortality outcome collected during the
short-term follow up (Egger’s test, P = 0.01; Begg’s
test, P = 0.18), as well as in the long-term (Egger’s
test, P = 0.03; Begg’s test, P = 0.02) (Appendix 2).
Table 2 Common pathogens involved in the pathogenesis of IEs
Pathogens/culture Patients with pathogens Total number of patients Overall estimate, 95% CI References
Culture positive 1320 2012 0.63(0.37–0.88) [22, 24–26, 28, 29, 31, 32, 35–38]
Culture negative 1049 12,508 0.21(0.09–0.42) [21, 22, 24–26, 31, 33, 35, 36, 38–41]
Staphylococcus aureus 2894 13,768 0.27(0.22–0.33) [19, 21, 22, 24–33, 36–41]
Streptococcus aureus 2426 13,768 0.23(0.18–0.29) [19, 21, 22, 24–33, 36–41]
Enterococci bacteria 313 2731 0.11(0.10–0.28) [19, 21, 22, 24–26, 39, 41]
HACEK and others 628 11,936 0.10(0.10–0.11) [19, 21, 22, 24–29, 31, 33, 36–40]
Abbreviation: HACEK Haemophilus, Aggregatibacter, Cardiobacterium hominis, Eikenella corrodens, Kingella species
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Discussion
To our knowledge, this is the first systematic review
and meta-analysis to explore the short-and long-term
outcomes in IE patients. In our meta-analysis, a
higher proportion of mortality was found in long-
term IE patients and the most frequently reported
type of IE was associated with native valve involve-
ment. Further analysis suggested that a significant
variation in percentage of patients with IE was no-
ticed between the sexes. Despite recent advancement
in treatment, IE remain a lethal disease following
surgery with long-term (1-year and 5-year) mortality
of 40% and 70%, respectively [24]. This is higher in
patients when the causative microorganism is
Staphylococcus aureus that causes serious valvular
damage and is also associated with higher
embolization and mortality [42]. A fifteen year co-
hort study has indicated more than 50% death over
a follow-up period of 89 months before the year
1995 [27]. Unlike our finding which reported 37%
mortality from long-term follow-up, this difference
might be due to the variation in the study period in
which our included studies were published after
2000, and in fact, many advanced changes in treat-
ment and care of IE patients may likely reduce this
occurrence. After short-term survivors of IE, a
twenty five years follow-up study indicated a long-
term survival rate of less than 50% [43]. Prospective
Fig. 2 Short-term outcome of infective endocarditis. *117 episodes of care for 106 patients were occurred and 117 was used as a denominator in
the calculation
Fig. 3 Long-term outcome of infective endocarditis
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study of non-drug addicts has found a long-term
mortality rate of 29% over ten year follow-up [43].
In the present study, native valve involvement was
frequently observed. A prospective cohort study
from 28 countries indicated that native valve IE was
a common scenario both in the community and hos-
pital settings [44]. This may be due to little to no ef-
fect of the use of prophylaxis for the prevention of
native valve IE during surgical procedures [45]. Evi-
dence obtained from seven electronic databases in
five countries indicated that mortality and staphylo-
coccus infections are more prominent in native valve
IE [46]. A multicenter cohort study has also revealed
that bacterial characteristics may contribute to the
occurrence of IE in patients with Staphylococcus
aureus bacteremia [47]. Multiple studies examined
the in-hospital and 30-days mortality in native valve
patients ranging from 3.2 to 15.5% [38, 48–51]. Our
findings discovered somewhat higher short-term
mortality, irrespective of the type of IE. The rela-
tively poor outcomes in short-term may be influ-
enced by multiple factors which include valve
characteristics, host factors, causative organisms, de-
velopment of intra-cardiac, or systemic complications
and the therapeutic options. Furthermore, more fre-
quent abscess formation and complete valve damage
may be associated with poor outcomes in short- and
long term-basis [51]. Although we did not analyze
mortality according the pathogen involved in IEs but
a previous study [52] demonstrated no difference in
mortality between culture negative and culture posi-
tive endocarditis. Still, Staphylococcus aureus
appeared as a leading pathogen, with an overall
in-hospital mortality rate of 45% [52]. In addition,
large vegetation size and presence of more than one vege-
tation are associated with higher probability of death [53].
Fig. 4 Cardiac complications of infective endocarditis. *117 episodes of care for 106 patients were occurred and 117 was used as a denominator
in the calculation. **Data for cardiac complication extracted from other presented data
Fig. 5 Embolic/septic complications of infective endocarditis
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In-hospital mortality could also be higher due to delayed
diagnosis and initiation of empiric therapy [54]. Similarly,
a previous study [55] revealed a significant difference in
mortality between native valve and prosthetic valve
endocarditis.
IE is one of the most common and serious complica-
tion of intravenous drug use (IVDU) which mainly in-
volve the tricuspid valve and the most isolated etiology
being Staphylococcus aureus, isolated in 68% of IVDU-IE
patients [56, 57]. Through this review, we identified the
occurrence of IE in IVDU was 18%. The absolute mor-
tality of IE in IVDU is difficult to find in the literatures.
Some studies estimated an in-hospital mortality ranging
from 5 to 20% [58, 59]. Another study identified that
acute infection accounted for approximately 60% of hos-
pital admission and that IVDU-IE was implicated in
5–15% of these episodes [60]. Predictive IE in IVDU pa-
tients includes cocaine use, and signs of septic emboli,
cavity, or effusion on chest x-ray [61].
The current study has also indicated that complica-
tions of IE were considered to be more prevalent.
Particularly, cardiac complications were more prominent
than renal and septic/embolic complications. This may
be due to the wide variety of manifestations of the car-
diac complications including peri-annular abscesses,
fistulae, acute coronary syndrome, and pericarditis [62].
But, neurologic complications were not examined in the
present study. Therefore, neurologic sequelae of IE is a
subject of interest and should be investigated in the
future perspective.
Additionally, in our study, the risk of developing IE
was higher in males than in females. This is consistent
with Levine et al. study [60], and in that study men with
IE were older than females (mean age: 32.7 years vs.
31.4 years) and have significantly lower histories of ad-
diction. Previous studies [63, 64] reported no significant
differences in in-hospital prognosis and mortality be-
tween men and women with left-sided IE. However, still
concrete evidence is scarce to support this claim.
Limitation of the study
The present review disclosed the rate of short- and
long-term mortality in IE patients. But, it is not
without limitations. Firstly, some of the studies in-
cluded in the review showed higher level of hetero-
geneity and we could not detect the source of
variation with the available data. While we planned
to stratify the primary outcomes into various covari-
ates, it was difficult to extract data in such a way
that allowed us to calculate sub-group analysis.
Secondly, some evidence of publication bias
confirmed in this review, suggesting that many
observational studies with rigorous designs are
warranted. Also, we urge cautious interpretation of
the pooled results given the limitation on our English
language search strategy coupled with fewer
databases searched. Thirdly, the strict quality assess-
ment score showed that six out of 25 studies were
low in quality and were thus, regarded to be at
higher risk of bias. In these studies, for instance,
sample size calculation was infrequently done and
underpowered. However, we conducted a sensitivity
analysis to avoid the ‘drowning effect’ from large
sample size studies – for example, one-on-one exclu-
sion of Ternhag et al. 2013 [17] and Shih et al. 2014
[33] in the short-term mortality did not differ from
the original overall estimates.
Conclusion
A significantly higher proportion of mortality was found
in short- and long-term follow-up of IE patients and the
most frequently reported type of IE was associated with
native valve involvement. The burden of IE complications
were higher among IE patients and were mostly cardiovas-
cular. In addition, a significantly higher IE rate was re-
ported in males than in females. Further research is
needed to assess the determinants of overall mortality in
IE patients, as well as well-designed observational studies
to conform our results.
Fig. 6 Renal complications of infective endocarditis. *117 episodes of care for 106 patients were occurred and 117 was used as a denominator in
the calculation
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Appendix 1
Fig. 7 Sub-group analysis. a. Types of IE. b. Sex
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Appendix 2
a Types of IE
b Sex
Fig. 8 Publication bias. a. Short-term mortality. b. Long-term mortality
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Additional file 1: Final excluded studies with reasons (1). Studies excluded
from the systematic review and meta-analysis after full text (N = 26). This file
contains list of studies that have been excluded during the literature review
process due to lack of fulfilling the inclusion criteria into the systematic
review and meta-analysis. (PDF 448 kb)
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